1363 - RAS (Kirsten RAS and Neuroblastoma RAS) mutation testing for eligibility for panitumumab treatment in previously untreated metastatic colorectal cancer patients

Page last updated: 21 June 2019

Application Detail



Description of Medical Service

The RAS mutation test is a combination of genetic tests, conducted on a biopsy sample, to tell whether a tumour carries a RAS mutation(s). KRAS and NRAS are highly related members of the RAS oncogene family which have an important role in the development and continued growth of colorectal cancer. The KRAS gene is found to be mutated, or changed, in about 40% of people with colorectal cancer. The NRAS gene is found to be mutated in an additional 10-15% of patients. The other ~50% of people have a non-mutated (sometimes called “wild type”) RAS genes.

Description of Medical Condition

Widespread colorectal cancer is treated with chemotherapy and patients may receive several sequential courses of different types of chemotherapy as the disease progresses. For patients with widespread disease the prognosis is poor with only 10% of patients still alive 5 years after diagnosis.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 181 KB)
Public Summary Document (Word 158 KB)

Predicted versus Actual

Public Summary Document - July 2018 (PDF 1252 KB)
Public Summary Document - July 2018 (Word 133 KB)

Meetings for this Application


Not required


12 and 13 June 2014


3 October 2014
27 July 2018